Adjuvant radiation therapy in small ductal carcinoma in situ. (February 2019)

• Record Type: Journal Article
• Authors: Cho, Won Kyung; Choi, Doo Ho; Kim, Haeyoung; Noh, Jae Myoung; Park, Won; Cha, Hyejung
• Is Part Of: Breast. Volume 43(2019)
• Page Start: 55
• Page End: 58
• Publication Date: 2019-02
• Subjects: Ductal carcinoma in situ -- Breast -- Radiotherapy; Breast -- Diseases -- Periodicals; Breast -- Tumors -- Periodicals; Breast -- Periodicals; Electronic journals; Periodicals; 616
• DOI: 10.1016/j.breast.2018.11.004
• Languages: English
• ISSNs: 0960-9776

Abstract

Abstract: Background: The objective of this study was to evaluate ipsilateral breast tumor recurrence (IBTR) rates in patients with small (≤1 cm) ductal carcinoma in situ (DCIS) who were followed up for more than 15 years. Methods: We identified 209 patients with primary small (≤1 cm) DCIS without invasion who received curative excision with and without adjuvant radiation therapy (RT) from 1996 to 2009. IBTR rates and prognostic factors in all patients were estimated by univariate and multivariate analyses. Results: With a median follow-up of 104 months, eight (53.3%) had DCIS recurrence and seven (46.7%) had recurrence of invasive ductal carcinoma. IBTR rate of all patients was 7.5% at 10 years and 12.1% at 15 years. In univariate analysis, age and subtypes were significant factors for IBTR. In multivariate analysis, resection margin, adjuvant RT, and endocrine therapy were significant factors for IBTR. Conclusions: IBTR rate of small (≤1 cm) DCIS following excision with or without adjuvant RT was 12.1% at 15 years. Adjuvant RT and endocrine therapy were associated with lower IBTR rate in small DCIS. Highlights: Ipsilateral breast tumor recurrence (IBTR) rate of small (≤1 cm) ductal carcinoma in situ (DCIS) was 12.1% at 15 years. Adjuvant radiation therapy and endocrine therapy were significant factors for IBTR. Together with appropriate endocrine therapy, adjuvant RT could lower IBTR in small DCIS.